• About Us
  • Advertise
  • Contact Us
  • Privacy Policy
  • Pickem Terms and Conditions
Sunday, February 5, 2023
The Platte County Landmark Newspaper
  • Home
  • Local News
  • Opinion
  • Landmark Pickem!
    • Weekly Pickem Updates
    • Results by Week
    • The Leaderboard
    • Pickem Rules and Help
  • Landmark Live!
  • Looking Backward
  • es_MXSpanish
  • Home
  • Local News
  • Opinion
  • Landmark Pickem!
    • Weekly Pickem Updates
    • Results by Week
    • The Leaderboard
    • Pickem Rules and Help
  • Landmark Live!
  • Looking Backward
  • es_MXSpanish
No Result
View All Result
The Platte County Landmark Newspaper
No Result
View All Result

Experimental COVID-19 vaccine has been ‘well-tolerated’

Landmark Staff by Landmark Staff
July 17, 2020
in Platte County
COVID-19
5
SHARES
131
VIEWS
Share on FacebookShare on TwitterShare via Email

An investigational vaccine, mRNA-1273, designed to protect against SARS-CoV-2, the virus that causes coronavirus disease 2019 (COVID-19), was generally well tolerated and prompted neutralizing antibody activity in healthy adults, according to interim results published online this week in The New England Journal of Medicine.

The ongoing Phase 1 trial is supported by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health. The experimental vaccine is being co-developed by researchers at NIAID and at Moderna, Inc. of Cambridge, Massachusetts. Manufactured by Moderna, mRNA-1273 is designed to induce neutralizing antibodies directed at a portion of the coronavirus “spike” protein, which the virus uses to bind to and enter human cells.

RelatedNews

Are you up for Immersive Yoga?

Let the gourd times roll

Gibson awarded as best
assistant prosecutor in state

The trial was led by Lisa A. Jackson, M.D., MPH, of Kaiser Permanente Washington Health Research Institute in Seattle, where the first participant received the candidate vaccine on March 16. This interim report details the initial findings from the first 45 participants ages 18 to 55 years enrolled at the study sites in Seattle and at Emory University in Atlanta. Three groups of 15 participants received two intramuscular injections, 28 days apart, of either 25, 100 or 250 micrograms (mcg) of the investigational vaccine. All the participants received one injection; 42 received both scheduled injections.

In April, the trial was expanded to enroll adults older than age 55 years; it now has 120 participants. However, the newly published results cover the 18 to 55-year age group only.

Regarding safety, no serious adverse events were reported. More than half of the participants reported fatigue, headache, chills, myalgia or pain at the injection site. Systemic adverse events were more common following the second vaccination and in those who received the highest vaccine dose. Data on side effects and immune responses at various vaccine dosages informed the doses used or planned for use in the Phase 2 and 3 clinical trials of the investigational vaccine.

The interim analysis includes results of tests measuring levels of vaccine-induced neutralizing activity through day 43 after the second injection. Two doses of vaccine prompted high levels of neutralizing antibody activity that were above the average values seen in convalescent sera obtained from persons with confirmed COVID-19 disease.

A Phase 2 clinical trial of mRNA-1273, sponsored by Moderna, began enrollment in late May. Plans are underway to launch a Phase 3 efficacy trial in July 2020.

Tags: covid-19
Landmark Staff

Landmark Staff

Related Posts

Platte County Resource Center

Sheriff’s office planning to move out of Platte City

by Ivan Foley
February 3, 2023
0

New home may be resource center near KCI A plan is in the works that would move the Platte County Sheriff’s Department headquarters out of the county seat of Platte City. As exclusively reported last week by The Landmark, the...

County getting ready to rearrange some chairs

County getting ready to rearrange some chairs

by Ivan Foley
January 27, 2023
0

I don’t think they’re rearranging the deck chairs on the Titanic, but they are getting ready to rearrange some chairs. Word seeped out--and by that I mean The Landmark heard about it from multiple sources--on Tuesday morning that county officials...

Goodcents

Where has the year gone?

by Ivan Foley
December 23, 2022
0

READ THIS TO FIND OUT It’s almost over. Where has the year gone? Sometimes the news happens so fast--even here in Platte County--that it’s hard to remember all the highlights. No worries, The Landmark has you covered. This week The...

Platte County Health Department

Health officials noting increase in respiratory illnesses

by Ivan Foley
December 8, 2022
0

AROUND 300 FLU CASES THUS FAR LOCALLY Like the majority of the United States, Missouri has been experiencing increased respiratory disease activity caused by multiple viruses, including flu and RSV that is occurring especially among children. Platte County Health Department...

Next Post

Advice for the health department

Popular News

  • Joe Vanover

    Vanover wins Sunshine Law trial

    15 shares
    Share 6 Tweet 4
  • Sheriff’s office planning to move out of Platte City

    11 shares
    Share 4 Tweet 3
  • KC’s new airport ready to fly on Feb. 28

    8 shares
    Share 3 Tweet 2
  • Culinary-inspired library planned at Green Hills

    98 shares
    Share 39 Tweet 25
  • Lawsuit claims toxic heavy metals in herbs and spices

    25 shares
    Share 10 Tweet 6
  • About Us
  • Advertise
  • Contact Us
  • Privacy Policy
  • Pickem Terms and Conditions
Call us at 816-858-0363

Copyright © 2019-2020 The Platte County Landmark Newspaper - All Rights Reserved

No Result
View All Result
  • Subscribe Online
  • Home
  • Local News
  • Opinion
  • Landmark Pickem
    • Login / Sign-up
    • Results by Week
    • The Leaderboard
    • Pickem Rules and Help
  • Landmark Live!
  • Looking Backward
  • es_MXSpanish

Copyright © 2019-2020 The Platte County Landmark Newspaper - All Rights Reserved